With a market cap of $23 billion, Incyte Corporation (INCY) is a Delaware–based biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies, primarily in oncology and inflammatory diseases. The company specializes in small-molecule drugs that modulate specific biological pathways, particularly those involved in cancer and immune system disorders.
The company is set to unveil its fiscal Q3 2026 results on Thursday, Oct. 29, before the market opens. Ahead of this event, analysts expect INCY to report a loss of $3.87 per share, down 290.6% from a profit of $2.03 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts forecast the specialty drugmaker to post EPS of $2.40, a 57% fall from $5.58 in fiscal 2025. Earnings are likely to rebound in FY2027, rising 217.5% year over year to $7.62.
www.barchart.comINCY stock has climbed 32.1% over the past 52 weeks, outperforming the broader S&P 500 Index's ($SPX) 15% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 16.4% return over the same period.
www.barchart.comIncyte has benefited from strong commercial growth, with revenue climbing 26.9% over the past year and averaging 22.8% annual growth over the last two years. Beyond top-line gains, the company has improved its cash-generating capacity, expanding its free cash flow margin by 12.6 percentage points over the past five years. Rising returns on invested capital have further strengthened its growth profile, helping INCY outpace the broader market.
On Sept. 25, Incyte and Mirum Pharmaceuticals, Inc. (MIRM) announced that the FDA has approved Atebrioz (zilurgisertib), a once-daily oral treatment designed to reduce abnormal bone formation in patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), a rare disease that progressively restricts movement. The approval was supported by clinical trial data showing a reduction in new bone lesion volume compared with placebo. Developed by Incyte and licensed to Mirum for commercialization, the treatment is expected to launch in the U.S. this month.
Analysts' consensus rating on INCY stock is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 28 analysts covering the stock, opinions include 12 "Strong Buy” and 16 "Holds.” Its mean price target of $130.56 implies an upswing potential of 15.8% from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
‘She’s Broke Now. She Just Doesn’t Know It’: Grant Cardone Says a SpaceX Employee Who Just Became a Millionaire and Sold Stock Is Making a Mistake Nasdaq Futures Climb as Chip Stocks Rebound on New OpenAI Revenue Report Arista Networks Stock Is Expensive, But Don’t Count It Out Just Yet How to Play AMD Stock as It Continues to Explore a Foundry Partnership With a Korean Tech Giant